20
Participants
Start Date
June 30, 2010
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2010
insulin degludec
Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
Novo Nordisk Investigational Site, Neuss
Lead Sponsor
Novo Nordisk A/S
INDUSTRY